Latest:
Triple-Negative Breast Cancer: Expert Perspectives On Recent Advances
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Adam S. Kibel, MD
Latest:
Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers
Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.
Adam Scott Feldman, MD, MPH
Latest:
Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.
Aditi Kumar, MD
Latest:
Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid Cancer
Aditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.
Latest:
Dr Bardia on Efficacy Data from the DESTINY-Breast06 Trial of T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer
Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.
Latest:
Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC
Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.
Latest:
Treatment Advances in HR+ Advanced Breast Cancer
Aditya Bardia, MD, MPH, discusses the current standard of care for HR+ advanced breast cancer and reacts to treatment advances with the availability of CDK4/6 inhibitors.
Aditya Juloori, MD
Latest:
Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment
Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.
Aditya V. Shreenivas, MD, MSCR
Aditya Shreenivas, M.D., M.S. is an assistant clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope.
Latest:
Dr Shreenivas on the FDA Approval of Penpulimab Plus Chemo for Frontline Non-Keratinizing Nasopharyngeal Carcinoma
Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.
Adria Suarez Mora, MD
Latest:
Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy
Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.
Adriana Rossi, MD, Weill Cornell Medical College
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers
Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.